Edition:
United Kingdom

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

722.60INR
15 Feb 2019
Change (% chg)

Rs-26.15 (-3.49%)
Prev Close
Rs748.75
Open
Rs749.95
Day's High
Rs749.95
Day's Low
Rs718.00
Volume
2,894,602
Avg. Vol
2,627,595
52-wk High
Rs830.45
52-wk Low
Rs527.00

Chart for

About

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system,... (more)

Overall

Beta: 0.84
Market Cap(Mil.): Rs437,068.31
Shares Outstanding(Mil.): 585.88
Dividend: 1.25
Yield (%): 0.52

Financials

  ARBN.NS Industry Sector
P/E (TTM): 19.51 30.48 33.70
EPS (TTM): 38.23 -- --
ROI: -- 14.95 14.45
ROE: -- 16.27 15.96

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the U.S.

A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.

02 Jan 2019

India's Aurobindo Pharma Q2 profit falls nearly 22 pct

Nov 12 Aurobindo Pharma Ltd, India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts' estimates.

12 Nov 2018

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

06 Sep 2018

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

06 Sep 2018

UPDATE 3-Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

* Deal to result in $70 mln impairment for Novartis (Adds related content, detail about impairment in third graf, updates shares)

06 Sep 2018

Novartis sells parts of Sandoz US to India's Aurobindo for $900 mln

Sept 6 Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India's Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.

06 Sep 2018

BRIEF-Novartis Says To Divest Sandoz U.S. Dermatology Business And Generic U.S. Oral Solids Portfolio To Aurobindo

* NOVARTIS TO DIVEST SANDOZ US DERMATOLOGY BUSINESS AND GENERIC US ORAL SOLIDS PORTFOLIO TO AUROBINDO

06 Sep 2018

BRIEF-Aurobindo Pharma Unit To Buy Commercial Ops And 3 Manufacturing Facilities From Sandoz

* UNIT AUROBINDO PHARMA USA ENTERED DEAL TO BUY COMMERCIAL OPERATIONS AND THREE MANUFACTURING FACILITIES IN USA FROM SANDOZ ., USA

06 Sep 2018

Earnings vs. Estimates